Compare
Schrodinger, Inc. vs Vireo Growth Inc. vs Harrow, Inc. vs Akebia Therapeutics, Inc.
| Latest fiscal year | Schrodinger, Inc. SDGR | Vireo Growth Inc. VREOF | Harrow, Inc. HROW | Akebia Therapeutics, Inc. AKBA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $255.87M | $268.77M | $272.30M | $236.20M |
| Revenue growth (YoY) | +23.3% | +170.4% | +36.4% | +47.5% |
| Gross margin | 55.7% | 47.3% | 75.1% | 83.3% (computed) |
| Operating margin | -65.2% | -0.4% | 11.2% | 9.9% |
| Net margin | -40.4% | -25.3% | -1.9% | -2.3% |
| Net income | -$103.27M | -$68.11M | -$5.14M | -$5.34M |
| EPS (Diluted) | -$1.41 | -$0.09 | -$0.14 | -$0.02 |
| Operating cash flow | $13.90M | $3.71M | $43.86M | $67.99M |
| Free cash flow | $12.46M | -$24.61M | $42.98M | $67.70M |
| Cash & equivalents | $230.52M | n/a | $72.93M | $184.84M |
| Total assets | $726.16M | $817.15M | $399.48M | $376.56M |
| Total liabilities | $362.11M | $509.73M | $347.39M | $343.95M |
| Shareholders' equity | $364.05M | $307.42M | $52.45M | $32.61M |
| Return on year-end equity | -28.4% | -22.2% | -9.8% | -16.4% |
| Shares outstanding | n/a | n/a | 37.23M | 265.42M |
Revenue, most recent five fiscal years
| Fiscal year | Schrodinger, Inc. | Vireo Growth Inc. | Harrow, Inc. | Akebia Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $255.87M Ended 2025-12-31 | $268.77M Ended 2025-12-31 | $272.30M Ended 2025-12-31 | $236.20M Ended 2025-12-31 |
| 1 year earlier | $207.54M Ended 2024-12-31 | $99.38M Ended 2024-12-31 | $199.61M Ended 2024-12-31 | $160.18M Ended 2024-12-31 |
| 2 years earlier | $216.67M Ended 2023-12-31 | $88.13M Ended 2023-12-31 | $130.19M Ended 2023-12-31 | $194.62M Ended 2023-12-31 |
| 3 years earlier | $180.96M Ended 2022-12-31 | $74.63M Ended 2022-12-31 | $88.59M Ended 2022-12-31 | $292.48M Ended 2022-12-31 |
| 4 years earlier | $137.93M Ended 2021-12-31 | $54.45M Ended 2021-12-31 | $72.48M Ended 2021-12-31 | $211.65M Ended 2021-12-31 |